BridgeBio Pharma, Inc. (BBIO)
- Sector
- Biotechnology
- Last price
- $70.82
- As of
Kresmion compiles this page from BBIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BridgeBio Pharma, Inc. (BBIO): 8 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-13.
See the full BBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the BBIO dossierActive events for BBIO
- high13F: funds added
10 tracked funds increased BBIO this 2026Q2, institutional consensus
- high13F: funds added
11 tracked funds increased BBIO this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 31.1%, EPS $-0.78 vs $-0.5951 estimate
- high13F: funds added
4 tracked funds increased BBIO this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +152% to BBIO (2026Q2)
FREE, NO ACCOUNT
Every event on BBIO, as it fires
You are seeing 5 of 28 events recorded on BBIO since 2026-06-10.
The five above landed across 4 days. The other 23 were recorded on 3 other days. 18 of the 28 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BBIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 10806X102 · 2026Q2 | $741M | 2.11% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 10806X102 · 2026Q2 | $351.7M | 0.25% | , |
| CITADEL ADVISORS LLCCUSIP 10806X102 · 2026Q2 | $280M | 0.03% | , |
| D. E. Shaw & Co., Inc.CUSIP 10806X102 · 2026Q2 | $270.6M | 0.13% | , |
| Point72 Asset Management, L.P.CUSIP 10806X102 · 2026Q2 | $113.6M | 0.13% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 10806X102 · 2026Q2 | $63.8M | 0.09% | , |
| CITADEL ADVISORS LLCCUSIP 10806XAJ1 · 2026Q2 | $48.8M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 10806X102 · 2026Q2 | $36.3M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 10806X102 · 2026Q2 | $33.4M | 0.14% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 10806XAB8 · 2026Q2 | $30.5M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 10806XAJ1 · 2026Q2 | $842K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BBIO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BBIO against its peers
BBIO's operating margin of -104.2% ranks in the 34th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-01-02.
| Metric | BBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 502M USD | 616M USD | 42 | 17 |
| Gross margin | 95.8% | 83.7% | 79 | 11 |
| Operating margin | -104.2% | -6.7% | 34 | 18 |
| Net margin | -146.0% | -19.2% | 34 | 18 |
| Return on equity | n/a | -11.8% | n/a | 19 |
| P / E | n/a | 31.1x | n/a | 7 |
Peers (23): HALO, NBIX, SMMT, ASND, EXEL, BMRN, APGE.D, KYMR, CAI, MDGL, NUVL.D, PCVX, KRYS, IBRX, SYRE, PTGX, INSM, CRNX.D, TGTX, BNTX, CYTK, ARWR, INCY. Left out: SBMFF (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-01-02. Every figure is one full fiscal year read from one annual filing (BBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BBIO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BBIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.